Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

NCT ID: NCT04472598

Last Updated: 2025-02-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

252 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-29

Study Completion Date

2025-01-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases risk of bleeding. Myelofibrosis often causes an enlarged spleen. The purpose of this study is to see if a combination of navitoclax and ruxolitinib is more effective and safe in assessment of change in spleen volume when compared to ruxolitinib in participants with myelofibrosis.

Navitoclax is an investigational drug for the treatment of myelofibrosis. Participants in this study are divided into two groups, called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of myelofibrosis will be enrolled. Around 230 participants will be enrolled in approximately 190 sites worldwide.

Participants will receive oral navitoclax tablet with oral ruxolitinib tablet or oral ruxolitinib tablet with oral placebo (no active drug) tablet and treatment may continue untill the participant cannot tolerate the study drug, or benefit is not achieved, or other reasons which qualify for discontinuation of the study drug.

There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, magnetic resonance imaging (MRI) or computed tomography (CT) scan, bone marrow tests, checking for side effects, and completing questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelofibrosis (MF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Navitoclax + Ruxolitinib

Participants will receive Navitoclax in combination with Ruxolitinib

Group Type EXPERIMENTAL

Navitoclax

Intervention Type DRUG

Tablet; Oral

Ruxolitinib

Intervention Type DRUG

Tablet; Oral

Placebo for Navitoclax + Ruxolitinib

Participants will receive placebo for Navitoclax and Ruxolitinib

Group Type ACTIVE_COMPARATOR

Ruxolitinib

Intervention Type DRUG

Tablet; Oral

Placebo for Navitoclax

Intervention Type DRUG

Tablet; Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Navitoclax

Tablet; Oral

Intervention Type DRUG

Ruxolitinib

Tablet; Oral

Intervention Type DRUG

Placebo for Navitoclax

Tablet; Oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABT-263

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented diagnosis of Primary MyeloFibrosis (MF) as defined by World Health Organization (WHO) classification or Secondary MF (post polycythemia vera \[PPV\] - MF or Post Essential Thrombocytopenia \[PET\] - MF) .
* Must be able to complete the MF Symptom Assessment Form (MFSAF) v4.0 on at least 4 out of 7 days immediately preceding the date of randomization.

\-- Must have at least 2 symptoms with a score \>=3 or a total score of \>=12, as measured by the MFSAF v4.0.
* Classified as intermediate-2, or high-Risk MF as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+).
* Has splenomegaly defined as spleen palpation measurement \>= 5 centimeters (cm) below costal margin or spleen volume greater than or equal to 450 cubic cm as assessed centrally by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
* Ineligible for stem cell transplantation at time of study entry due to age, comorbidities, or unfit for unrelated or unmatched donor transplant and other criteria per National Comprehensive Cancer Network guidelines.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

Exclusion Criteria

* Prior treatment with a Janus Kinase-2 (JAK-2) inhibitor.
* Prior treatment with a B-cell lymphoma 2 homology 3 (BH3)-mimetic compound or bromodomain and extra-terminal motif (BET) inhibitor or stem cell transplant.
* Receiving medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period except for low dose aspirin (up to 100 milligram daily) and low molecular weight heparin (LMWH).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Highlands Oncology Group, PA /ID# 221824

Springdale, Arkansas, United States

Site Status

Providence - St. Jude Medical Center /ID# 241646

Fullerton, California, United States

Site Status

Moores Cancer Center at UC San Diego /ID# 218012

La Jolla, California, United States

Site Status

Rocky Mountain Cancer Centers - Littleton /ID# 222562

Littleton, Colorado, United States

Site Status

Lynn Cancer Institute, Boca /ID# 230687

Boca Raton, Florida, United States

Site Status

Florida Cancer Specialist - South /ID# 221726

Fort Myers, Florida, United States

Site Status

Florida Cancer Specialists - North /ID# 221727

St. Petersburg, Florida, United States

Site Status

Florida Cancer Specialists - East /ID# 221728

West Palm Beach, Florida, United States

Site Status

Emory University /ID# 221562

Atlanta, Georgia, United States

Site Status

Augusta University Georgia Cancer Center /ID# 221551

Augusta, Georgia, United States

Site Status

Columbus Regional Research Institute /ID# 227272

Columbus, Georgia, United States

Site Status

Duplicate_Rush University Medical Center /ID# 221581

Chicago, Illinois, United States

Site Status

Mid Illinois Hematology & Oncology Associates, Ltd /ID# 224204

Normal, Illinois, United States

Site Status

Indiana Blood & Marrow Transpl /ID# 221586

Indianapolis, Indiana, United States

Site Status

University of Kansas Cancer Center /ID# 218144

Fairway, Kansas, United States

Site Status

Massachusetts General Hospital /ID# 221559

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Medical Center /ID# 224261

Boston, Massachusetts, United States

Site Status

Dana-Farber Cancer Institute /ID# 218010

Boston, Massachusetts, United States

Site Status

University of Michigan /ID# 221658

Ann Arbor, Michigan, United States

Site Status

Minnesota Oncology Hematology /ID# 227357

Edina, Minnesota, United States

Site Status

MidAmerica Division, Inc. /ID# 221743

Kansas City, Missouri, United States

Site Status

Hackensack Univ Med Ctr /ID# 221654

Hackensack, New Jersey, United States

Site Status

Northwell Health - Monter Cancer Center /ID# 222996

Lake Success, New York, United States

Site Status

Weill Cornell Medical College /ID# 220933

New York, New York, United States

Site Status

Gabrail Cancer Center Research /ID# 230488

Canton, Ohio, United States

Site Status

Oncology Hematology Care, Inc. /ID# 222556

Cincinnati, Ohio, United States

Site Status

The Ohio State University /ID# 221584

Columbus, Ohio, United States

Site Status

UPMC Hillman Cancer Ctr /ID# 218134

Pittsburgh, Pennsylvania, United States

Site Status

Thompson Cancer Survival Ctr /ID# 231689

Knoxville, Tennessee, United States

Site Status

University of Texas MD Anderson Cancer Center /ID# 217994

Houston, Texas, United States

Site Status

Texas Oncology - Northeast Texas /ID# 241813

Tyler, Texas, United States

Site Status

Utah Cancer Specialists Salt Lake Clinic /ID# 221961

Salt Lake City, Utah, United States

Site Status

University of Utah /ID# 221009

Salt Lake City, Utah, United States

Site Status

Virginia Cancer Specialists - Fairfax /ID# 242682

Fairfax, Virginia, United States

Site Status

VA Puget Sound Health Care System /ID# 231691

Seattle, Washington, United States

Site Status

The Kinghorn Cancer Centre /ID# 221503

Darlinghurst, New South Wales, Australia

Site Status

Border Medical Oncology Research Unit Albury Wodonga Regiona /ID# 231311

East Albury, New South Wales, Australia

Site Status

Gosford Hospital /ID# 221499

Gosford, New South Wales, Australia

Site Status

Liverpool Hospital /ID# 221803

Liverpool, New South Wales, Australia

Site Status

Townsville University Hospital /ID# 229794

Douglas, Queensland, Australia

Site Status

Peter MacCallum Cancer Ctr /ID# 229795

Melbourne, Victoria, Australia

Site Status

The Alfred Hospital /ID# 221501

Melbourne, Victoria, Australia

Site Status

Royal Perth Hospital /ID# 223203

Perth, Western Australia, Australia

Site Status

Duplicate_Medizinische Universitaet Graz /ID# 220910

Graz, Styria, Austria

Site Status

Ordensklinikum Linz GmbH Elisabethinen /ID# 220813

Linz, Upper Austria, Austria

Site Status

Klinikum Wels-Grieskirchen GmbH /ID# 220901

Wels, Upper Austria, Austria

Site Status

Medizinische Universitaet Wien /ID# 220906

Vienna, Vienna, Austria

Site Status

Hanusch Krankenhaus /ID# 220909

Vienna, , Austria

Site Status

ZAS Cadix /ID# 221465

Antwerp, Antwerpen, Belgium

Site Status

CHU de Liège /ID# 218874

Liège, Liege, Belgium

Site Status

Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 221127

Yvoir, Namur, Belgium

Site Status

UZ Gent /ID# 221125

Ghent, Oost-Vlaanderen, Belgium

Site Status

Vitaz /Id# 229861

Sint-Niklaas, Oost-Vlaanderen, Belgium

Site Status

Universitair Ziekenhuis Leuven /ID# 218806

Leuven, Vlaams-Brabant, Belgium

Site Status

AZ-Delta /ID# 221466

Roeselare, West-Vlaanderen, Belgium

Site Status

AZ Sint-Jan Brugge /ID# 218805

Bruges, , Belgium

Site Status

UMHAT Alexandrovska EAD /ID# 231056

Sofiya, Sofia, Bulgaria

Site Status

UMHAT Dr Georgi Stranski EAD /ID# 231161

Pleven, , Bulgaria

Site Status

UMHAT Sveti Georgi /ID# 231053

Plovdiv, , Bulgaria

Site Status

Acibadem City Clinic Tokuda University Hospital EAD /ID# 231036

Sofia, , Bulgaria

Site Status

UMHAT Sveti Ivan Rilski /ID# 231028

Sofia, , Bulgaria

Site Status

Royal Victoria Hospital /ID# 222636

Barrie, Ontario, Canada

Site Status

Juravinski Cancer Centre /ID# 221752

Hamilton, Ontario, Canada

Site Status

Lakeridge Health - Oshawa /ID# 222080

Oshawa, Ontario, Canada

Site Status

Niagara Health System /ID# 230994

St. Catharines, Ontario, Canada

Site Status

CHUQ- Hôpital de l'Enfant-Jesus /ID# 221754

Québec, Quebec, Canada

Site Status

Clinical Hospital Dubrava /ID# 230795

Zagreb, City of Zagreb, Croatia

Site Status

Klinicka bolnica Merkur /ID# 231155

Zagreb, City of Zagreb, Croatia

Site Status

Klinicki bolnicki centar Zagreb /ID# 230793

Zagreb, City of Zagreb, Croatia

Site Status

Duplicate_Klinicki bolnicki centar Split /ID# 230796

Split, Split-Dalmatia County, Croatia

Site Status

CHU NIMES - Hopital Caremeau /ID# 219114

Nîmes, Gard, France

Site Status

Centre Hospitalier Universitaire de Bordeaux /ID# 222518

Pessac, Gironde, France

Site Status

CH Roubaix - Hopital Victor Provo /ID# 219116

Roubaix, Hauts-de-France, France

Site Status

CHU de Nantes, Hotel Dieu -HME /ID# 219113

Nantes, Pays de la Loire Region, France

Site Status

HCL - Hopital Lyon Sud /ID# 222913

Pierre-Bénite, Rhone, France

Site Status

Centre Hospitalier Métropole Savoie - Site Hôpital de Chambéry /ID# 224506

Chambéry, Savoie, France

Site Status

Chu Angers /Id# 219115

Angers, , France

Site Status

Hôpital Saint-Louis /ID# 221288

Paris, , France

Site Status

AP-HP - Hopital Necker /ID# 231318

Paris, , France

Site Status

ICANS - Institut de Cancérologie Strasbourg Europe /ID# 229978

Strasbourg, , France

Site Status

Hopital Avicenne - APHP /ID# 221286

Bobigny, Île-de-France Region, France

Site Status

Universitatsklinikum Mannheim /ID# 221523

Mannheim, Baden-Wurttemberg, Germany

Site Status

Haemato-Onkologie /ID# 221061

Munich, Bavaria, Germany

Site Status

Universitaetsklinikum Aachen /ID# 221519

Aachen, North Rhine-Westphalia, Germany

Site Status

BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 221347

Dresden, Saxony, Germany

Site Status

Universitaetsklinikum Essen /ID# 221522

Essen, , Germany

Site Status

OncoResearch Lerchenfeld GmbH /ID# 230867

Hamburg, , Germany

Site Status

Klinikum rechts der Isar /ID# 221520

Munich, , Germany

Site Status

General Hospital of Athens Laiko /ID# 230785

Athens, Attica, Greece

Site Status

Duplicate_University General Hospital Attikon /ID# 230784

Athens, Attica, Greece

Site Status

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 230786

Athens, , Greece

Site Status

Meir Medical Center /ID# 221374

Kfar Saba, Central District, Israel

Site Status

Yitzhak Shamir Medical Center /ID# 222957

Ẕerifin, Central District, Israel

Site Status

Rambam Health Care Campus /ID# 219120

Haifa, H_efa, Israel

Site Status

Hadassah Medical Center-Hebrew University /ID# 219110

Jerusalem, Jerusalem, Israel

Site Status

The Chaim Sheba Medical Center /ID# 219137

Ramat Gan, Tel Aviv, Israel

Site Status

Tel Aviv Sourasky Medical Center /ID# 219134

Tel Aviv, Tel Aviv, Israel

Site Status

IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 220867

Bologna, Emilia-Romagna, Italy

Site Status

Azienda Ospedaliero Universitaria Careggi /ID# 219086

Florence, Firenze, Italy

Site Status

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 219083

Rome, Roma, Italy

Site Status

ASST Papa Giovanni XXIII /ID# 221907

Bergamo, , Italy

Site Status

ASST degli Spedali Civili di Brescia /ID# 241273

Brescia, , Italy

Site Status

AOU Policlinico G. Rodolico - San Marco /ID# 219085

Catania, , Italy

Site Status

Duplicate_ASST Sette Laghi /ID# 219084

Varese, , Italy

Site Status

Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 239100

Nagoya, Aichi-ken, Japan

Site Status

Fujita Health University Hospital /ID# 221537

Toyoake, Aichi-ken, Japan

Site Status

Duplicate_Chiba University Hospital /ID# 239345

Chiba, Chiba, Japan

Site Status

National Cancer Center Hospital East /ID# 226093

Kashiwa-shi, Chiba, Japan

Site Status

Ehime University Hospital /ID# 221443

Toon-shi, Ehime, Japan

Site Status

Kyushu University Hospital /ID# 221783

Fukuoka, Fukuoka, Japan

Site Status

Fukushima Medical University Hospital /ID# 222752

Fukushima, Fukushima, Japan

Site Status

Ogaki Municipal Hospital /ID# 240173

Ogaki-shi, Gifu, Japan

Site Status

Gunmaken Saiseikai Maebashi Hospital /ID# 242806

Maebashi, Gunma, Japan

Site Status

Gunma University Hospital /ID# 221480

Maebashi, Gunma, Japan

Site Status

Duplicate_Hokkaido University Hospital /ID# 242667

Sapporo, Hokkaido, Japan

Site Status

Kobe University Hospital /ID# 246236

Kobe, Hyōgo, Japan

Site Status

Hitachi General Hospital /ID# 240048

Hitachi-shi, Ibaraki, Japan

Site Status

Kanazawa University Hospital /ID# 238424

Kanazawa, Ishikawa-ken, Japan

Site Status

Medical Corporation Seijinkai Ikeda Hospital /ID# 242172

Kanoya-shi, Kagoshima-ken, Japan

Site Status

Kyoto University Hospital /ID# 238423

Kyoto, Kyoto, Japan

Site Status

Mie University Hospital /ID# 221664

Tsu, Mie-ken, Japan

Site Status

University of Miyazaki Hospital /ID# 221483

Miyazaki, Miyazaki, Japan

Site Status

Duplicate_Kawasaki Medical School Hospital /ID# 221481

Kurashiki-shi, Okayama-ken, Japan

Site Status

Kurashiki Central Hospital /ID# 221692

Kurashiki-shi, Okayama-ken, Japan

Site Status

Kansai Medical University Hospital /ID# 221482

Hirakata-shi, Osaka, Japan

Site Status

Kindai University Hospital /ID# 221479

Osakasayama-shi, Osaka, Japan

Site Status

Osaka University Hospital /ID# 221478

Suita-shi, Osaka, Japan

Site Status

Dokkyo Medical University Saitama Medical Center /ID# 222333

Koshigaya, Saitama, Japan

Site Status

Juntendo University Shizuoka Hospital /ID# 221782

Izunokuni-shi, Shizuoka, Japan

Site Status

Juntendo University Hospital /ID# 221405

Bunkyo-ku, Tokyo, Japan

Site Status

Nippon Medical School Hospital /ID# 221674

Bunkyo-ku, Tokyo, Japan

Site Status

University of Yamanashi Hospital /ID# 221701

Chuo-shi, Yamanashi, Japan

Site Status

Radboud Universitair Medisch Centrum /ID# 218948

Nijmegen, Gelderland, Netherlands

Site Status

Albert Schweitzer Ziekenhuis /ID# 224015

Dordrecht, South Holland, Netherlands

Site Status

Universitair Medisch Centrum Groningen /ID# 218947

Groningen, , Netherlands

Site Status

Universitair Medisch Centrum Utrecht /ID# 218949

Utrecht, , Netherlands

Site Status

Aotearoa Clinical Trials /ID# 230770

Papatoetoe, Auckland, New Zealand

Site Status

Moscow State budget healthcare /ID# 221025

Moscow, Moscow, Russia

Site Status

Republican hospital named after V.A. Baranov /ID# 221412

Petrozavodsk, Murmansk Oblast, Russia

Site Status

Clinic UZI 4D /ID# 221024

Pyatigorsk, Stavropol Kray, Russia

Site Status

Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 221029

Saint Petersburg, , Russia

Site Status

Leningrad Regional Clinical Hospital /ID# 221028

Saint Petersburg, , Russia

Site Status

Almazov National Medical Research Centre /ID# 221033

Saint Petersburg, , Russia

Site Status

Tula Regional Clinical Hospital /ID# 221027

Tula, , Russia

Site Status

University Clinical Center Serbia /ID# 230854

Belgrade, Beograd, Serbia

Site Status

Clin Hosp Ctr Bezanijska Kosa /ID# 230946

Belgrade, Beograd, Serbia

Site Status

University Clinical Center Kragujevac /ID# 230855

Kragujevac, Pomoravski Okrug, Serbia

Site Status

Duplicate_Clinical Center Vojvodina /ID# 230853

Novi Sad, Vojvodina, Serbia

Site Status

Wits Clinical Research /ID# 232072

Johannesburg, Gauteng, South Africa

Site Status

Duplicate_Wits Clinical Research Site /ID# 232071

Johannesburg, Gauteng, South Africa

Site Status

Alberts Cellular Therapy /ID# 232073

Pretoria, Gauteng, South Africa

Site Status

Duplicate_Inje University Busan Paik Hospital /ID# 231667

Busan, Busan Gwang Yeogsi, South Korea

Site Status

Pusan National University Hospital /ID# 222087

Busan, Busan Gwang Yeogsi, South Korea

Site Status

Duplicate_Kyungpook National University Hospital /ID# 231666

Daegu, Daegu Gwang Yeogsi, South Korea

Site Status

Gachon University Gil Medical Center /ID# 222089

Incheon, Gyeonggido, South Korea

Site Status

Duplicate_Seoul National University Bundang Hospital /ID# 219053

Seongnam, Gyeonggido, South Korea

Site Status

Seoul National University Hospital /ID# 219055

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Asan Medical Center /ID# 219054

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Samsung Medical Center /ID# 221068

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

The Catholic University of Korea, Seoul St. Marys Hospital /ID# 219056

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Duplicate_Hospital Clínico Universitario de Santiago-CHUS /ID# 222264

Santiago de Compostela, A Coruna, Spain

Site Status

Hospital Universitario Germans Trias i Pujol /ID# 229936

Badalona, Barcelona, Spain

Site Status

Hospital Universitario Dr. Negrin /ID# 220897

Las Palmas de Gran Canaria, Las Palmas, Spain

Site Status

Clinica Universidad de Navarra - Pamplona /ID# 230720

Pamplona, Navarre, Spain

Site Status

Hospital Parc de Salut del Mar /ID# 220913

Barcelona, , Spain

Site Status

Hospital Universitario Vall d'Hebron /ID# 229690

Barcelona, , Spain

Site Status

CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 230721

Madrid, , Spain

Site Status

Hospital Universitario Ramon y Cajal /ID# 220877

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre /ID# 229691

Madrid, , Spain

Site Status

Hospital Universitario Virgen de la Victoria /ID# 220878

Málaga, , Spain

Site Status

Hospital Clinico Universitario de Valencia /ID# 220875

Valencia, , Spain

Site Status

Duplicate_Skane University Hospital Lund /ID# 220835

Lund, Skåne County, Sweden

Site Status

Duplicate_Sahlgrenska University Hospital /ID# 218776

Gothenburg, Västra Götaland County, Sweden

Site Status

Orebro Universitetssjukhuset /ID# 220829

Örebro, Örebro County, Sweden

Site Status

Kaohsiung Chang Gung Memorial Hospital /ID# 218984

Kaohsiung City, Kaohsiung, Taiwan

Site Status

Chi Mei Hospital - Liouying /ID# 221145

Tainan City, Tainan, Taiwan

Site Status

National Taiwan University Hospital /ID# 218976

Taipei City, Taipei, Taiwan

Site Status

China Medical University Hospital /ID# 218978

Taichung, , Taiwan

Site Status

Taipei Veterans General Hosp /ID# 221146

Taipei, , Taiwan

Site Status

Linkou Chang Gung Memorial Hospital /ID# 218983

Taoyuan, , Taiwan

Site Status

Hacettepe University Medical Faculty /ID# 230759

Ankara, , Turkey (Türkiye)

Site Status

Trakya University Medical Facu /ID# 230754

Edirne, Istanbul, , Turkey (Türkiye)

Site Status

Bagcilar Medipol Mega Universite Hastanesi /ID# 230757

Istanbul, , Turkey (Türkiye)

Site Status

Ege University Medical Faculty /ID# 230753

Izmir, , Turkey (Türkiye)

Site Status

Inonu University Medical Faculty /ID# 230758

Malatya, , Turkey (Türkiye)

Site Status

Communal non-profit enterprise Regional Center of Oncology /ID# 230832

Kharkiv, Kharkivs’ka Oblast’, Ukraine

Site Status

Medical Center OK Clinic LLC, International Institute of Clinical Research /ID# 230834

Kyiv, , Ukraine

Site Status

Feofaniya Clinical Hospital of State Management of Affairs /ID# 232370

Kyiv, , Ukraine

Site Status

SI Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine /ID# 230833

Lviv, , Ukraine

Site Status

Guys and St Thomas NHS Foundation Trust /ID# 219185

London, Greater London, United Kingdom

Site Status

United Lincolnshire Hospitals NHS Trust /ID# 231471

Lincoln, Lincolnshire, United Kingdom

Site Status

Oxford University Hospitals NHS Foundation Trust /ID# 219192

Oxford, Oxfordshire, United Kingdom

Site Status

University Hospitals Birmingham NHS Foundation Trust /ID# 221333

Birmingham, , United Kingdom

Site Status

The Christie Hospital /ID# 219191

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Bulgaria Canada Croatia France Germany Greece Israel Italy Japan Netherlands New Zealand Russia Serbia South Africa South Korea Spain Sweden Taiwan Turkey (Türkiye) Ukraine United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-000097-15

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

M16-191

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.